sulfametopyrazine
Small moleculeexperimental
Sulfalene or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria. As of 2014 there were only two countries in which it is currently still marketed: Thailand and Ireland. — Wikipedia
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started May 1, 2006 (NCT00484900)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
OC(=O)CCC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=NC=CS2- Mol. weight
- 355.389 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSulfalene ↗
- NCATSRSS8647O4S ↗
- ChEMBLCHEMBL268869 ↗
- ChEMBLCHEMBL1525826 ↗
- ChEMBLCHEMBL1484857 ↗
Also known as
- cremosuxidine
- kaoxidin
- kaoxidine
- kelfizina
- kelfizina
- kelfizina
- kelfizine w
- kelfizine w
- lederkyn
- lederkyn
- midicel
- midicel
- solfametopirazina
- solfametopirazina
- succinylsulfathi
- succinylsulfathiazole
- succinylsulfathiazole
- succinylsulfathiazole
- succinylsulfathiazole
- succinylsulphathiazole
- sulfadigesin
- sulfalene
- sulfalene
- sulfalene
- sulfalene
- sulfalene
- sulfaleno
- sulfaleno
- sulfalenum
- sulfalenum
- sulfamethopyrazine
- sulfamethopyrazine
- sulfamethopyrazine
- sulfamethoxypyrazine
- sulfamethoxypyrazine
- sulfamethoxypyrazine
- sulfamethoxypyridazine
- sulfamethoxypyridazine
- sulfametopyrazine
- sulfametopyrazine
- sulfametopyrazine
- sulfametopyrazine
- sulfametopyrazine
- sulfapyrazinemethoxine
- sulfapyrazinemethoxyine
- sulfapyrazinemethoxyne
- sulfasuccidin
- sulfasuccidine
- sulfasuccinil
- sulfasuccithiazole
- sulfasuxidine
- sulfasuxidine
- sulfasuxidine
- sulfenterone
- sulphamethopyrazine
- sulphamethopyrazine
- sulphamethopyrazine
- sulphamethopyrazine
- sulphamethopyrazine
- sulphamethopyrazine
- sulphamethoxypyridazine
- sulphamethoxypyridazine
- sulphamethoxypyridazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01054651 | Phase 3 | Oct 1, 2009 | Dafra Pharma, Kenya Medical Research Institute |
| NCT00510159 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2007 | Dafra Pharma, University of Bamako |
| NCT00484900 | Phase 3 | May 1, 2006 | Dafra Pharma, Kigali Central University Hospital, Rwanda, University of Bamako, University of Khartoum |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dafra Pharma | For profit | 3 | 2 | 1 | 2006 |
| University of Bamako | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Kigali Central University Hospital, Rwanda | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Khartoum | Academic/Hospital | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1